Good
Mostly Aligned
Patient Risk:
Low
Summary
The claim “WARNING: RISK OF THYROID C-CELL TUMORS” is supported by the provided label excerpts describing rodent thyroid C-cell tumors, the unknown human relevance, and contraindications for MTC/MEN 2 with related counseling. However, exact boxed-warning wording/heading linkage is not fully verifiable from the text provided (label numbering/heading mapping uncertainty).
Category Scores
Accurate Statements
“WARNING: RISK OF THYROID C-CELL TUMORS.”
Supported by provided label content in Section 5.1 describing thyroid C-cell tumors in mice and rats, unknown human relevance, contraindication context, and patient counseling (also referenced to Boxed Warning/5.1).
Contraindicated in patients with personal or family history of medullary thyroid cancer (MTC) or MEN 2.
Section 4 Contraindications and Section 5.1 state OZEMPIC is contraindicated in patients with personal/family history of MTC or MEN 2.
Patients should be counseled regarding potential risk for MTC and symptoms such as neck mass, dysphagia, dyspnea, and persistent hoarseness.
Section 5.1 and Section 17 include symptom counseling (neck lump/mass, hoarseness, dysphagia, dyspnea).
Routine monitoring with serum calcitonin or thyroid ultrasound has uncertain value for early detection.
Section 5.1 states routine monitoring is of uncertain value for early detection and may increase unnecessary procedures.
Unsupported Statements
That the claim text itself is the exact FDA boxed-warning heading/wording as it appears in the label.
The provided excerpt includes Section 5.1 content and references to Boxed Warning, but it does not provide the verbatim boxed-warning text/heading, nor does it definitively confirm the exact boxed-warning section number/label formatting for the heading phrase.
Contradictions
Important Omissions
The label’s specific guidance that routine calcitonin/ultrasound monitoring is of uncertain value and may increase unnecessary procedures (if the AI response implied or omitted monitoring guidance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The core warning concept (thyroid C-cell tumor risk in rodents and unknown human relevance) and key contraindication/counseling elements are supported by the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The exact boxed-warning heading/wording is not fully verifiable from the provided excerpts.
Suggested Improvement
Quote or reference the verbatim boxed-warning text/heading (as provided in the label) and ensure the citation matches the boxed-warning section/heading exactly.